Avalo Therapeutics
AVTX
37 hedge funds and large institutions have $148M invested in Avalo Therapeutics in 2019 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 4 closing their positions.
71% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 7
67% more capital invested
Capital invested by funds: $88.3M → $148M (+$59.4M)
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
3% more funds holding
Funds holding: 36 → 37 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more ownership
Funds ownership: 0.02% → 0.02% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
+$232K |
| 2 |
State Street
Boston,
Massachusetts
|
+$179K |
| 3 |
BlackRock
New York
|
+$148K |
| 4 |
Morgan Stanley
New York
|
+$84.4K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$52.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$305K |
| 2 |
SIM
Spark Investment Management
New York
|
-$148K |
| 3 |
JP Morgan Chase
New York
|
-$94.9K |
| 4 |
WG
Winton Group
London,
United Kingdom
|
-$63.3K |
| 5 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$35K |
AVTX Hedge Fund Activity: Q4 2019 in Review
37 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q4 2019, worth a combined $148M — up 67% from $88.3M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new AVTX positions and 4 closed out — a net gain of 1 holder — while 12 added to existing stakes and 7 trimmed.
The largest buyer was Boothbay Fund Management, adding an estimated $232K. The largest seller was Millennium Management, exiting entirely with an estimated $305K sold.
- 37 institutional investors held Avalo Therapeutics (AVTX) as of Q4 2019, up from 36 in Q3 2019.
- Funds reported $148M of Avalo Therapeutics stock for Q4 2019, up 67% quarter-over-quarter.
- 5 funds opened new Avalo Therapeutics positions in Q4 2019 and 4 closed out, a net change of +1 holder.
- The largest Avalo Therapeutics buyer in Q4 2019 was Boothbay Fund Management, an estimated $232K added.
- The largest Avalo Therapeutics seller in Q4 2019 was Millennium Management, an estimated $305K sold.
Based on aggregated 13F filings for Q4 2019.